Accord BioPharma’s HERCESSI secures FDA approval
Pharmaceutical Technology
APRIL 30, 2024
Accord BioPharma, the division of Intas Pharmaceuticals, has secured approval from the US FDA for HERCESSI, a biosimilar to Herceptin.
Tue.Apr 30, 2024
biopharma-fda 
52 
From viral vectors to nucleic acids: biopharma’s evolving manufacturing landscape
European Pharmaceutical Review
APRIL 30, 2024
What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? I believe this is going to be an emerging trend in the market.
Let's personalize your content